Helus Pharma Inc. - Common Stock (HELP)

8.1033
-0.7667 (-8.64%)
NASDAQ · Last Trade: Nov 16th, 1:23 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close8.870
Open9.000
Bid8.100
Ask8.130
Day's Range6.900 - 9.570
52 Week Range3.760 - 15.15
Volume11,332,567
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume1,418,258

Chart

News & Press Releases

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · November 16, 2026
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 3 Results for HLP003 in Major Depressive Disorder, Meeting Primary and Key Secondary Endpoints
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · November 16, 2026
Premarket Movers on Nov. 16, 2026: Gainers and Declinerschartmill.com
Via Chartmill · November 16, 2026
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points
By Helus Pharma Inc. · Via GlobeNewswire · November 16, 2026
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization 
By Helus Pharma Inc. · Via GlobeNewswire · November 16, 2026
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026
By Helus Pharma Inc. · Via GlobeNewswire · November 15, 2026
Cybin Expects Key Phase III Depression Trial Results This Quartermarketbeat.com
Helus Pharma expects results from the first Phase III trial of its experimental adjunctive treatment for major depressive disorder later this quarter, CEO Michael Halstead said at the Guggenheim Healthcare Innovation Conference. The company’s 003 program, a deuterated psilocin treatment, is being s
Via MarketBeat · November 10, 2026
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Guggenheim Healthcare Innovation Conference Nov. 9
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · November 3, 2026
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT
By Helus Pharma Inc. · Via GlobeNewswire · November 3, 2026
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Announces Leadership Transition, Appoints Mark Lawson Independent Board Chair
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · October 27, 2026
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
Co-founders to step down from executive roles and continue to serve on the Board of Directors
By Helus Pharma Inc. · Via GlobeNewswire · October 27, 2026
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Highlights Phase 3 HLP003 Readout Timeline and Plans for HLP004 Phase 2 Study
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · October 22, 2026
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2
By Helus Pharma Inc. · Via GlobeNewswire · October 21, 2026
Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advancesmarketbeat.com
Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth quarter of 2026. Helus Pharma Chief Executive Officer Michael Halstead said the company is developin
Via MarketBeat · October 21, 2026
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints CNS Drug Development Veteran Suresh Durgam to Board of Directors
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · October 15, 2026
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
By Helus Pharma Inc. · Via GlobeNewswire · October 15, 2026
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Host Investor Presentation Highlighting Depression and Anxiety Treatment Programs on Oct. 21
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · October 8, 2026
Helus Pharma to Host Investor Presentation on October 21, 2026
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.
By Helus Pharma Inc. · Via GlobeNewswire · October 8, 2026
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Changes Legal Name from Cybin Inc.
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · October 1, 2026
Helus Pharma Announces Completion of Legal Name Change
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company’s annual and special meeting of shareholders held on September 22, 2026. The name change follows the Company’s adoption of the business name “Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.
By Helus Pharma · Via GlobeNewswire · October 1, 2026
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depressionmarketbeat.com
Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen’s Novel Mechanisms in Neuropsychiatry virtual summit. Michael Halstead
Via MarketBeat · September 24, 2026
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · September 23, 2026
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
By Helus Pharma · Via GlobeNewswire · September 22, 2026
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Boardmarketbeat.com
Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections. Eric So, the company’s co-founder and executiv
Via MarketBeat · September 22, 2026
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Via Investor Brand Network · September 22, 2026